Worth reading
45Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
45.5
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 July 2025 to 31 March 2026ConsolidatedJapanese GAAPNet Sales108,366¥ millionYear on year +18.0%Progress 76.8%
Operating profit37,414¥ millionYear on year +45.5%Progress 88.6%
Ordinary income37,207¥ millionYear on year +45.4%Progress 87.2%
Net income attributable to owners of the parent26,657¥ millionYear on year +204.2%Progress 87.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥100.13
Financial position at period-end
Total assets203,730¥ million
of which net assets 167,159 ¥ millionEquity ratio 81.6%vs. prior year-end +3.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical Business ¥94,766 million (YoY +14.6%), Device business ¥13,600 million (YoY +49.5%)
Segment profitMedical Business ¥36,132 million (YoY +31.8%), Device business ¥7,274 million (YoY +88.6%)
Regional salesRegion Japan / Current fiscal year ¥15,395 million / Prior-year period ¥14,052 million, Region North America / Current fiscal year ¥23,933 million / Prior-year period ¥19,907 million, Region Europe / Current fiscal year ¥21,760 million / Prior-year period ¥18,448 million, Region China / Current fiscal year ¥28,549 million / Prior-year period ¥23,506 million, Region Other / Current fiscal year ¥18,727 million / Prior-year period ¥15,900 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥141,142 million (YoY +17.6%)
Operating profit¥42,220 million (YoY +40.4%)
Ordinary income¥42,688 million (YoY +44.4%)
Net income¥30,556 million (YoY +139.9%)
Annual Dividend Forecast¥24.23 → ¥46.1（+90.3%）
Factors Behind Changes in Business Performance
Both the Medical Business and Device Business performed strongly, resulting in higher sales across all regions and major product categories. The gross profit margin increased due to higher sales and improved productivity, while impairment losses decreased substantially. In the Device Business, the consolidation of Nitta Mold Co., Ltd. and its subsidiaries also contributed to the increase in sales.
Disclosure regarding the going concern assumption
No applicable matters (There are no applicable matters.)
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 2 / Company name ニッタモールド株式会社, NITTA M&T(THAILAND)CO.,LTD. / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable matters.
Impairment loss¥0 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥1,527 million / Extraordinary loss Impairment loss on investment securities ¥156 million, Loss on sale of investment securities ¥6 million, Impairment Losses on Shares of Affiliates ¥784 million
Depreciation and amortization¥6,618 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End265,332,300 shares
Treasury Shares at Period-End7,977 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥108,366 million (YoY +18.0%) |
| Operating profit | ¥37,414 million (YoY +45.5%) |
| Ordinary income | ¥37,207 million (YoY +45.4%) |
| Profit attributable to owners of the parent | ¥26,657 million (YoY +204.2%) |
| Net income per share | ¥100.13 |
| Equity ratio | End of the current fiscal period 81.6 / End of previous period 77.9 |
| Total assets | ¥203,730 million |
| Net assets | ¥167,159 million |
| Full-year earnings forecast | Net Sales ¥141,142 million (YoY +17.6%) / Operating profit ¥42,220 million (YoY +40.4%) / Ordinary income ¥42,688 million (YoY +44.4%) / Net income ¥30,556 million (YoY +139.9%) |
| Annual Dividend Forecast | ¥24.23 → ¥46.1（+90.3%） |
| Segment revenue | Medical Business ¥94,766 million (YoY +14.6%), Device business ¥13,600 million (YoY +49.5%) |
| Segment profit | Medical Business ¥36,132 million (YoY +31.8%), Device business ¥7,274 million (YoY +88.6%) |
| Regional sales | Region Japan / Current fiscal year ¥15,395 million / Prior-year period ¥14,052 million, Region North America / Current fiscal year ¥23,933 million / Prior-year period ¥19,907 million, Region Europe / Current fiscal year ¥21,760 million / Prior-year period ¥18,448 million, Region China / Current fiscal year ¥28,549 million / Prior-year period ¥23,506 million, Region Other / Current fiscal year ¥18,727 million / Prior-year period ¥15,900 million |
| Depreciation and amortization | ¥6,618 million |
| Impairment loss | ¥0 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥1,527 million / Extraordinary loss Impairment loss on investment securities ¥156 million, Loss on sale of investment securities ¥6 million, Impairment Losses on Shares of Affiliates ¥784 million |
| Disclosure regarding the going concern assumption | No applicable matters (There are no applicable matters.) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 2 / Company name ニッタモールド株式会社, NITTA M&T(THAILAND)CO.,LTD. / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 265,332,300 shares |
| Treasury Shares at Period-End | 7,977 shares |
| Factors Behind Changes in Business Performance | Both the Medical Business and Device Business performed strongly, resulting in higher sales across all regions and major product categories. The gross profit margin increased due to higher sales and improved productivity, while impairment losses decreased substantially. In the Device Business, the consolidation of Nitta Mold Co., Ltd. and its subsidiaries also contributed to the increase in sales. |
Items this document does not state (9)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main reasons were strong performance in both the Medical Business and Device Business, an increase in the gross profit margin due to higher sales and improved productivity, and a substantial decrease in impairment losses. In the Device Business, the consolidation of Nitta Mold Co., Ltd. and its subsidiaries also contributed to the increase in sales.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.